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ChemotherapyAbstract Background: To explore the activity of pazopanib in solitary ﬁbrous tumour (SFT).
Patients and methods: In a preclinical study, we compared the activity of pazopanib,
sorafenib, sunitinib, regorafenib, axitinib and bevacizumab in a dedifferentiated-SFT (DSFT)
xenotransplanted into Severe Combined Immunodeﬁciency (SCID) mice. Antiangiogenics
were administered at their reported optimal doses when mean tumour volume (TV) was
80 mm3. Drug activity was assessed as TV inhibition percentage (TVI%). From May 2012,
six consecutive patients with advanced SFT received pazopanib, on a national name-based
programme. In one case sunitinib was administered after pazopanib failure.ax: +39
3022 S. Stacchiotti et al. / European Journal of Cancer 50 (2014) 3021–3028Results: In the xenograft model, pazopanib showed the lowest antitumour activity (21%TVI),
while regorafenib was the most active (95%TVI). Sorafenib, bevacizumab, sunitinib were
markedly active (78/70/65%TVI). Axitinib was marginally active (51%TVI).
In the retrospective case-series, three patients carried malignant-SFT (MSFT), three DSFT.
Best Response Evaluation Criteria in Solid Tumour (RECIST) responses were: three stable
disease (SD), all MSFT, three progressive disease (PD), all DSFT, corresponding to one
partial response (PR), two SD, three PD by Choi criteria. Median-progression-free survival
was 3 months (range 1–15). In one patient, sunitinib was started after pazopanib failure, with
a response.
Conclusions: In dedifferentiated-SFT xenograft pazopanib induced a marginal antitumour
activity, while regorafenib appeared the most active and promising agent. When administered
in patients, pazopanib showed a modest activity in terms of tumour growth stabilisation,
observed only in non-dedifferentiated cases.
 2014 Elsevier Ltd. All rights reserved.1. Introduction
Pazopanib is an inhibitor of vascular endothelial
growth factor receptor (VEGFR) 1–3 recently approved
for treatment of non-adipocytic advanced soft tissue
sarcoma (STS) after failure to front-line chemotherapy
[1]. In a Phase 3 study on pazopanib in non-adipocytic
STS the median progression-free survival (PFS) was
4.6 months for pazopanib compared with 1.6 months
for placebo, with an overall survival (OS) of
12.5 months versus 10.7 months [2].
Very few data are available on the activity of pazop-
anib in solitary ﬁbrous tumour (SFT), a rare STS sub-
type [3], the sensitivity of which to antiangiogenics like
sorafenib, sunitinib and bevacizumab is reported [4–9].
Antiangiogenics were shown to produce durable disease
stabilisation in a proportion of patients by means of
tumour responses that were mostly non-dimensional
[5,6]. We already reported on the activity of pazopanib
in a human high-grade dediﬀerentiated-SFT xenotrans-
planted into severe combined immunodeﬁciency (SCID)
mice [10]. When compared to dacarbazine and temozol-
omide, pazopanib was less active and characterised by a
short lasting cytostatic eﬀect. Thus, we decided to
expand that experiment to a broader number of antian-
giogenic agents (i.e. sorafenib, regorafenib, axitinib in
addition to sunitinib and bevacizumab) already applied
in the clinical practice. Our ﬁndings are reported herein.
Within a name-based protocol following the results
of the Phase 3 trial, we treated with pazopanib six
patients aﬀected by SFT. We report herein their out-
come as well.2. Patients and methods
2.1. Experimental model and pharmacological studies
A patient-derived human high-grade dediﬀerentiated-
SFT xenograft model [10] was used in the study. The pres-
ence of the typicalNAB2-STAT6 rearrangement – recentlydescribed in human SFT [12] – was conﬁrmed in xenograft
by RT-PCR [10].
The xenograft model was maintained by serial sub-
cutis (s.c.) passages in 6 week-old female SCID mice
(Charles River, Calco, IT). Brieﬂy, when tumours
reached approximately 500 mm3, they were removed,
aseptically dissected, cut into small fragments
(3  3  3 mm) and s.c. implanted in the mouse right
ﬂank. Twenty-four hours after tumour inoculum,
100 lL of Matrigel Basement Matrix (BD Biosciences)
was injected intratumourally. Mice were housed in a
pathogen-free facility with free access to food and water.
Tumour growth was followed by biweekly measurement
of tumour diameters with a Vernier caliper, and tumour
volume (TV) was calculated according to the following
formula: TV (mm3) = d2  D/2, where d and D are the
shortest and the longest diameter, respectively.2.1.1. Xenograft treatment
Treatment was started when xenotransplanted
tumourswere approximately 80 mm3 (day 35). Eightmice
for each group were used. Pazopanib, sorafenib, suniti-
nib, regorafenib and axitinib were all dissolved in 0.5%
carboxymethylcellulose and delivered by oral gavage
5 days/week for 4 weeks (qd  5d/w  4w)  2 after a
3-week rest at their reported optimal dose of 100/60/40/
30 and 2  25 mg/kg, respectively. Bevacizumab was
delivered intraperitoneally twice a week for 4 weeks
(q3–4d/w  4w)  2 after a 3-week rest at its reported
optimal dose of 4 mg/kg [12–16]. Control mice were
treated with vehicle.
Antitumour activity was assessed as tumour volume
inhibition percentage (TVI%) in treated versus control
mice (TVI% = 100  (T/C  100)  100, where T and
C are the mean tumour volume of treated and control
mice, respectively). Drug toxicity was determined as
body weight loss and lethal toxicity.
The use of patient material in xenograft and all the
experiments were approved by the Ethics Committee
for Animal Experimentation of Fondazione IRCCS
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pliance with national and international law and policies.2.1.2. PDGFRB, VEGFR2 and ERK1/2 expression/
activation
PDGFRB expression/activation was analysed by
Western blotting (WB) on 20 lg of protein lysates using
anti-PDGFRB (1:1000; #4564; Cell Signaling Technol-
ogy, Danvers, MA) and anti-phospho-PDGFRB
(1:1000; #3166 Tyr751; Cell Signaling Technology)
antibodies. Anti-actin antibody (1:2500; A2066;
Sigma–Aldrich, St. Luis, MO) was used to ensure equal
loading of proteins and to normalise the results.
VEGFR2 was analysed by immunoprecipitation (IP)/
WB: equal amounts (1 mg) of protein lysates were pre-
cipitated by incubation with anti-VEGFR2 Sepharose
bead Conjugate (#5168; Cell Signaling Technology).
WB was carried-out using anti-phosphotyrosine anti-
body (1:3000; 05–321; Merck Millipore, Billerica, MA)
to detect VEGFR2 activation. The ﬁlters were stripped
and incubated with anti-VEGFR2 antibody (1:1000;
#2479; Cell Signaling Technology) to evaluate VEGFR2
degree of expression.
ERK1/2 expression and activation were evaluated by
WB on 20 lg of protein lysates using anti-phospho-
MAPK (1:1000; #4376 Thr202/Tyr204; Cell Signaling
Technology) and anti-MAPK (1:1000; #9102 p44/42;
Cell Signaling Technology) antibodies. Anti-actin anti-
body was used to ensure equal loading of proteins and
to normalise the results.2.2. Patients
We identiﬁed six patients with metastatic SFT con-
secutively treated within the Italian name-based pro-
gramme on pazopanib in advanced STS, open from
May 2012 to May 2013. Patients were treated at INT
and in other four Italian institutions. Only cases whose
diagnosis was centrally conﬁrmed by expert sarcoma
pathologists (SP and APDT) are included in this study.
Performance status (ECOG) 6 3, adequate bone
marrow and organ function, past medical history nega-
tive for deep vein thrombosis, pulmonary embolism or
cerebral vascular disorder were requested.
All patients provided a written informed consent to
the treatment with pazopanib. Approval by each Institu-
tional Review Board was also required.2.2.1. Treatment
Patients received oral pazopanib 800 mg/day (i.e.
400 mg  2/day), continuously, until progression or tox-
icity. Treatment was withheld for haematologic grade
(G)P 3 and for non-haematologic GP 2 adverse
events (AE) as deﬁned according to the National Cancer
Institute Common Toxicity Criteria, version 3.0, andrestarted after recovery to G < 2 in case of haematologic
or G < 1 in case of non-haematologic.
2.2.2. Clinical assessment
Biochemistry and blood count were evaluated at
baseline and monitored throughout the study period.
AE were recorded. Disease status was assessed by whole
body computed tomography scan (CT) and a CT of the
sites of disease at baseline and repeated after 4–6 weeks
of treatment, at 2–3 months, then every 3 months.
2.2.3. Eﬃcacy assessment
All cases were centrally reviewed at INT. Response to
treatment was assessed by Response Evaluation Criteria
in Solid Tumour (RECIST), version 1.1, and by Choi
criteria [17]. Choi criteria are based on changes in
tumour size (>10% maximum diameter) and density
following contrast administration on CT.
OS and PFS were estimated using the Kaplan–Meier
method. Patients without evidence of progression and
interrupting treatment with pazopanib for any reason
were censored at the last tumour assessment. Patients
alive or lost to follow-up were censored at the last
contact.
2.2.4. Morphology and immunophenotype
Diagnosis was centrally reviewed according to the
last World Health Organisation (WHO) classiﬁcation
[3]. All selected cases were positive for CD34 and
STAT6. Two additional cases included in the named-
base programme were excluded from this study since
SFT diagnosis was not conﬁrmed by pathologic review.
2.2.5. Role of the funding source
Glaxo Smith Kline provided pazopanib on a case by
case basis, and was informed of the results. The corre-
sponding author had the ﬁnal responsibility for the deci-
sion to submit the paper for publication, and wrote the
manuscript with all the other authors. The Company
played no role in writing or revising the manuscript.
3. Results
3.1. Experimental model and pharmacological studies
3.1.1. Antitumour activity studies
A signiﬁcant tumour growth inhibition was observed
following treatment with the diﬀerent anti-angiogenic
agents, even if at a diﬀerent extent. The only exception
was pazopanib that showed a negligible antitumour
eﬀect throughout the experiment (Fig. 1, Table 1). After
the ﬁrst 4 weeks of treatment, the antitumour eﬀect was
maximum for regorafenib and less pronounced for
sorafenib, sunitinib, bevacizumab and axitinib. In all
the treated animal groups, tumour growth was resumed
following drug withdrawal, although diﬀerent growth
Fig. 1. Eﬃcacy of pazopanib and other antiangionenic drugs against solitary ﬁbrous tumour xenotransplanted into SCID mice. The treatment
duration is indicated by the grey bar.
Table 1
Antitumour activity of pazopanib and other antiangiogenic drugs on solitary ﬁbrous tumour xenograft.
Drug Dose (mg/kg) Schedule Route Max TVI% (day)
Pazopanib 100 qd  5d/w  4w  2 p.o 21 (86)
Sorafenib 60 qd  5d/w  4w  2 p.o 78 (58)**
Sunitinib 40 qd  5d/w  4w  2 p.o 65 (51)**
Regorafenib 30 qd  5d/w  4w  2 p.o 95 (65)**
Axitinib 25 2qd  5d/w  4w  2 p.o 51 (54)*
Bevacizumab 4 q3-4d/w  4w  2 i.p 70 (89)**
*p < 0.05 and **p < 0.01 versus controls: Student’s t test; TVI: tumour volume inhibition.
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compounds. In the case of regorafenib and sorafenib,
the second run (4 weeks) of treatment, delivered after
a 3-week rest, stabilised tumour volume for the duration
of treatment (Fig. 1).
No sign of toxicity was registered, with the exception
of regorafenib that caused a 10% body weight loss
during the second run of treatment.3.1.2. Pathologic evaluation of drug-treated xenograft
Pathologic evaluation was carried-out on tumour
samples obtained after 2 h from the last drug adminis-
tration, at the end of the ﬁrst and of the second run of
treatment. No histological changes were observed
between treated and untreated tumours.Fig. 2. Biochemical analyses of samples derived from mice treated
with anti-angiogenic drugs. Panel A: Western blotting (WB) analysis of
PDGFRB. Panel B: Immunoprecipitation/WB of VEGFR2. Panel C:
WB analysis of ERK1/2. Mice were treated with sorafenib (b), axitinib
(c), pazopanib (d), regorafenib (f), sunitinib (g), bevacizumab (h) for
4 weeks. No treated mice were used as control (a and e). The P-
PDGFRB, P-Tyr, P-ERK1/2 panels identify the phosphorylated
proteins; PDGFRB, VEGFR2, ERK1/2 panels indicate the expression
of the corresponding proteins. Anti-actin antibody was used to
normalise the results.3.1.3. PDGFRB, VEGFR2 and ERK1/2 expression/
activation
After the ﬁrst 4 weeks of treatment sorafenib induced
a decrease in PDGFRB expression/activation, regorafe-
nib and especially axitinib induced a decrease in
PDGFRB activation, while sunitinib, bevacizumab
and pazopanib did not (Fig. 2A). Sunitinib, bev-
acizumab and regorafenib induced a weak decrease of
VEGFR2 activation, while all the other treatments did
not (Fig. 2B). The only drug that induced a decrease
Table 2
Patient characteristics and clinical ﬁndings.
Patient
ID
Sex Primary
tumour site
Prior
chemotherapy
(response)
Age at time of
pazopanib
(years)
Tumour type at
time of
pazopanib
Disease
extension
Best Response Evaluation
Criteria in Solid Tumour
(RECIST) response
Best
Choi
response
PFS
(mos)
1 F Pelvis Yes (NV) 53 MSFT Abdomen, bone SD SD 5
2 F Pleura Yes (NV) 73 MSFT Thoraco-abdominal
wall, bone
SD SD 3
3 M Pleura Yes (stable
disease)
63 DSFT Thoracic wall, lung PD PD 1
5 M Pleura Yes (no) 75 DSFT Lung, soft tissue PD PD 2
6 F Abdomen Yes (no) 77 MSFT Abdomen, lung SD PR 15
7 M Kidney Yes (yes) 33 DSFT Lung, soft tissue,
bone
PD PD 2
F: female; M: male; NV: not valuable; MSFT: malignant solitary ﬁbrous tumour; DSFT: dediﬀerentiated solitary ﬁbrous tumour; SD: stable
disease; PD: progressive disease; PR: partial response; PFS: progression free survival; mos: months.
Fig. 3. Response to pazopanib. Computed tomography (CT) scan (arterial phase after contrast medium). Panel A shows a intrathoracic lesion
from pleural solitary ﬁbrous tumour at baseline. Three months after starting pazopanib a response was observed, marked by a decrease in tumour
size and pleural eﬀusion, and a decrease in tumour density (Panel B).
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axitinib (Fig. 2C, line c) but this result was not con-
ﬁrmed by the analysis performed on the tumour samples
excised after the second run (data not shown).3.2. Patients
Six patients received pazopanib from May 2012 to
October 2013. All cases completed their treatment (four
progression; two toxicity) and were evaluable for
response.3.2.1. Patients
Table 2 summarises clinical ﬁndings.
Mean age was 62 years. PS was 62 in all cases. All
patients had progressed before starting treatment.
Morphology was consistent with a diagnosis of malig-
nant-SFT in three patients and dediﬀerentiated-SFT in
the other three.
Median treatment duration was 3 months (range: 1–
15). All patients started pazopanib 800 mg/day. Twopatients interrupted deﬁnitively their treatment due to
toxicity (G3 liver toxicity: 1; G3 cardiac toxicity: 1).
Toxicity resolved upon discontinuation.3.2.2. Response
Best RECIST responses were three stable disease
(SD) and three progressive disease (PD). According to
Choi criteria best response was partial response (PR)
in one, conﬁrmed at 3 months, SD in two and PD in
three (Fig. 3).
At a median 10-month follow-up, three patients are
alive, three dead. Median PFS by RECIST was
3 months (range 1–15).
In one patient progressive under pazopanib, sunitinib
37.5 mg/day was started with response after 3 months
(Fig. 4).4. Discussion
In a mouse model of dediﬀerentiated-SFT, pazopanib
showed the lowest antitumour activity (21%TVI), when
Fig. 4. Response to sunitinib after failure to pazopanib. Computed tomography (CT) scan (arterial phase after contrast medium). Panel A shows a
pelvic lesion from pelvic solitary ﬁbrous tumour at baseline. Three months after starting pazopanib a progression was observed, marked by an
increase in tumour size and contrast uptake was observed (Panel B). On this basis pazopanib was interrupted and sunitinib was started with
evidence of response 3 months later in terms of minor tumour shrinkage and hypodensity (Panel C).
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nib and sunitinib, while regorafenib was the most active
compound (95%TVI). Sorafenib, bevacizumab and suni-
tinib were also markedly active (78%, 70% and 65%TVI,
respectively), whereas axitinib was marginally active
(51%TVI). In a series of six patients with progressing
metastatic SFT treated with pazopanib, the best
responses according to RECIST were three SD and three
PD, corresponding to one PR, two SD, three PD by Choi
criteria, with a 3-month median PFS. All patients show-
ing a tumour disease stabilisation under pazopanib were
malignant-SFT, while those who progressed were high-
grade dediﬀerentiated-SFT. Interestingly a response
was subsequently obtained administering sunitinib in a
patient who did not respond to pazopanib.
SFT represents a very rare disease and very few data
are available on its sensitivity to pazopanib, that is the
only antiangiogenic agent approved for STS treatment.
Our preclinical results showed that pazopanib is less
active compared to other antiangiogenics in a high-grade
dediﬀerentiated-SFT mouse model [10]. By contrast
regorafenib was found to be the most interesting com-
pound. All the tested antiangiogenics showed a cytostatic
eﬀect. In all cases, indeed, tumour re-growth was
observed after treatment discontinuation. This is
consistent with the evidence that tumour samples after
treatment with the diﬀerent agents were made by viable
cells in all cases. Of interest, among RTK inhibitors,
pazopanib and axitinib were found to be less active than
sunitinib, sorafenib and regorafenib. In particular,pazopanib could obtain only a very modest decrease in
tumour growth compared to control. A clear explanation
for that is not yet available. The larger spectrum of kinase
inhibition that marks sunitinib and especially sorafenib
and regorafenib compared to pazopanib could make
the diﬀerence. This hypothesis is corroborated by the evi-
dence that, among the diﬀerent antiangiogenics, only
treatment reiteration (after a 3-week rest) with sorafenib
and regorafenib, i.e. the two drugs with the largest
spectrum of targets, was able to stabilise tumour volume.
Biochemical analysis of PDGFRB, VEGFR2 and
ERK1/2 after treatment showed that pazopanib did not
switch-oﬀ any of the targets, consistently with its mar-
ginal activity. In contrast to what we expected, a decrease
in kinase activation was not detected even in tumour sam-
ples which have responded to treatment. The presence of
viable tumour cells in post-treatment samples even in
tumours that signiﬁcantly shrank strongly suggests the
presence of resistant cells. We lack a deﬁnitive explana-
tion for this observation and new experiments are in place
to further investigate the diﬀerent sensitivity of our SFT
model to the antiangiogenics. We recently found that the
antitumour eﬀect of sunitinib in SFT patients is
ascribable, at least in part, to antiangiogenic drug immu-
nomodulating functions [18]. However, it is diﬃcult to
envisage such an eﬀect in our patient-derived xenografts
growing into immunodeﬁcient hosts, such as SCID mice.
To be noticed, the inhibitory eﬀect of the diﬀerent
antiangiogenics on their target proteins is characterised
by a diﬀerent kinetics. As a consequence, the evaluation
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we made in our experiment, could have prevented the
possibility to compare properly the biochemical eﬀects
of the diﬀerent compounds. We have started new experi-
ments in tumour samples obtained at diﬀerent intervals
from mice treated with the diﬀerent agents aimed at
comparatively evaluating changes in the transcriptome
as well as in the phosphorylation status of proteins
belonging to relevant pathways.
The French group already reported on two SD out
of six SFT patients treated with pazopanib (PFS 8
and 14 months, respectively) [9]. Our clinical data,
even if retrospective and on a small number of
patients, conﬁrm that pazopanib had a modest activity
in this sarcoma subtype and, interestingly, are in line
with the preclinical results. No RECIST responses
could be observed but in one patient the eﬀect of
pazopanib was marked by a minor (<30%) decrease
in tumour size and by a decrease in tumour density,
thus classifying for a PR by Choi criteria [11]. As
already described for SFT treated with bevacizumab,
sunitinib and sorafenib, Choi criteria [4–9], originally
conceived for GIST receiving imatinib [11], diﬀered
from RECIST in assessing response to therapy. Of
note, the patient with a Choi response had the best
PFS (15 months). Our results seem to suggest a lower
level of activity of pazopanib in SFT compared to
sunitinib and bevacizumab plus temozolomide [5,6].
Median PFS of patients treated with pazopanib was
3 months, while a retrospective study on sunitinib in
31 SFT patients showed a Choi RR of about 50% with
a 6-month median PFS [5]. Again, a Choi RR of 79%
with a median PFS of 9.7 months was reported in SFT
patients treated with bevacizumab and temozolomide
[6]. Interestingly, patients who progressed under paz-
opanib had dediﬀerentiated-SFT, while the responsive
case carried a malignant-SFT. This observation sug-
gests that pazopanib might be more active in less
aggressive cases, as already observed in SFT patients
treated with sunitinib, and by contrast to what was
observed with cytotoxic chemotherapy [19]. Worth
noting, we obtained a response to sunitinib in a patient
progressive to pazopanib consistently with the preclin-
ical evidence of a non-superimposable activity of
antiangiogenics in SFT.
Our results need to be conﬁrmed prospectively. A
European study on pazopanib in advanced SFT aimed
at evaluating Choi response as primary end-point has
just started. In addition, based on preclinical data
showing that regorafenib is the most promising antian-
giogenic agent, a prospective study on regorafenib in
SFT is actually under discussion.
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